2021年度全球肺高血压领域大事件盘点
魏云鹏,郭帆,黎婧怡,梅可怡,吴小寒,荆志成
摘要(Abstract)：
<正>肺高血压是一类进展性、恶化性心血管疾病，其真正的发病机制尚未阐明。回顾2021年，肺高血压领域涌现出大量精彩的临床和基础研究，为我们探讨肺高血压的发病机制、寻求新的治疗方式提供了重要参考，也为该类患者群体带来了新希望。本文逐一盘点2021年度肺高血压领域研究的重大进展，为2022年开展工作提供重要参考资料。
关键词(KeyWords)： 肺高血压;治疗;新药研发;靶点
基金项目(Foundation): 中国医学科学院医学与健康科技创新工程项目（2021-I2M-1-018）
作者(Author): 魏云鹏,郭帆,黎婧怡,梅可怡,吴小寒,荆志成
参考文献(References)：
- [1] Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension[J]. N Engl J Med,2021, 384(13):1204-1215.
- [2] Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease[J]. N Engl J Med, 2021, 384(4):325-334.
- [3] Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension:a post-hoc analysis of the INCREASE study[J]. Lancet Respir Med, 2021, 9(11):1266-1274.
- [4] Nathan SD, Tapson VF, Elwing J, et al. E ffi cacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial[J]. Am J Respir Crit Care Med, 2022, 205(2):198-207.
- [5] Jiang X, Zhu YJ, Zhou YP, et al. Clinical features and survival in Takayasu’s arteritis-associated pulmonary hypertension:a nationwide study[J]. Eur Heart J, 2021, 42(42):4298-4305.
- [6] Chin KM, Sitbon O, Doelberg M, et al. Three-versus twodrug therapy for patients with newly diagnosed pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2021, 78(14):1393-1403.
- [7] Grady RM, Canter MW, Wan F, et al. Pulmonary-to-systemic arterial shunt to treat children with severe pulmonary hypertension[J].J Am Coll Cardiol, 2021, 78(5):468-477.
- [8] Grünig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension:results from a large European multicentre randomized controlled trial[J]. Eur Heart J, 2021, 42(23):2284-2295.
- [9] Zhu L, Liu F, Hao Q, et al. Dietary geranylgeranyl pyrophosphate counteracts the benefi ts of statin therapy in experimental pulmonary hypertension[J]. Circulation,2021, 143(18):1775-1792.
- [10] Bisserier M, Mathiyalagan P, Zhang S, et al. Regulation of the methylation and expression levels of the BMPR2 gene by SIN3a as a novel therapeutic mechanism in pulmonary arterial hypertension[J].Circulation, 2021, 144(1):52-73.
- [11] Hong J, Arneson D, Umar S, et al. Single-cell study of two rat models of pulmonary arterial hypertension reveals connections to human pathobiology and drug repositioning[J]. Am J Respir Crit Care Med, 2021, 203(8):1006-1022.
- [12] Gu M, Donato M, Guo M, et al. iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296for pulmonary arterial hypertension[J]. Sci Transl Med, 2021, 13(592):eaba6480.